Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Editor’s note: No newsletter tomorrow on account of Easter - have a good long weekend and see you on Monday!

Eli Lilly's Foundayo (oral orforglipron) wins FDA approval for obesity treatment following Ph3 success
Small molecule, metabolic, obesity, GLP-1 receptor agonist, orforglipron - Read more

Axsome Therapeutics, Takeda partner on schizophrenia asset balipodect with undisclosed upfront, milestone payments
Licensing deal, neurological, small molecule, milestone payments - Read more

Zai Lab, Amgen collaborate on global Phase 1b trial combining zocilurtatug pelitecan with IMDELLTRA for small cell lung cancer
Research collaboration, oncology, antibody-drug conjugate, bispecific T-cell engager - Read more

Janux Therapeutics, Bristol Myers Squibb achieve development candidate milestone, triggering $35 million payment
Research collaboration, oncology, milestone payments, immunotherapy - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Alphamab Oncology's anbenitamab hits Ph3 primary endpoint targeting HER2 in neoadjuvant breast cancer treatment
Antibody, cancer, bispecific antibody, breast cancer, HER2, neoadjuvant therapy - Read more

Oric Pharmaceuticals advances rinzimetostat PRC2 inhibitor into Ph3 trial for metastatic castration-resistant prostate cancer
Small molecule, cancer, PRC2 inhibitor, metastatic castration-resistant prostate cancer, combination therapy - Read more

Syneron Bio raises $150M Series B, advancing macrocyclic peptide drug discovery platform
Macrocyclic peptide, drug discovery, oncology, autoimmune, platform technology - Read more

TippingPoint Biosciences raises $4.5M Seed, chromatin-targeted drug discovery platform
Epigenetic platform, cancer, neurological, chromatin targeting, drug discovery, preclinical - Read more

Semarion raises $3.8M funding, drug screening solutions with SemaCyte platform
Drug screening, platform technology, biotechnology services, materials engineering - Read more

Apollomics raises $2M bridge financing for clinical development programs
Clinical-stage, oncology - Read more

Celldex Therapeutics raises $300M public offering, commercial launch and pipeline development
Antibody, bispecific antibody platform, autoimmune, clinical-stage - Read more

INOVIO Pharmaceuticals announces proposed public offering, developing DNA medicines for diseases
DNA medicines, cancer, infectious disease, HPV-related diseases - Read more

Brussels court orders Poland, Romania to pay nearly €2B ($2.31B) to Pfizer and BioNTech for undelivered Covid vaccines
mRNA vaccine, infectious disease, regulatory, major transaction - Read more

Korsana Biosciences to go public via Cyclerion Therapeutics reverse merger with $380M funding
Monoclonal antibody, neurological, strategic, major transaction - Read more

CapVest completes majority acquisition of STADA, a leading healthcare and pharmaceuticals company
Generics, consumer healthcare, strategic, major transaction - Read more

NHS expands Wegovy access to 1.2M high cardiovascular risk patients following NICE recommendation
GLP-1 agonist, cardiovascular, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Pfizer and BioNTech halt US Ph3 trial for Comirnaty COVID-19 vaccine due to recruitment challenges
Vaccine, infectious disease, mRNA vaccine, COVID-19, booster, clinical trial recruitment - Read more

Alto Neuroscience reports mixed Ph2 results for ALTO-101 targeting cognitive impairment associated with schizophrenia
Small molecule, neurological, PDE4 inhibitor, schizophrenia, cognitive impairment, modified-release formulation - Read more

FDA delays Orca Bio's Orca-T allogeneic T-cell therapy approval decision to July for hematologic malignancies
Cell therapy, cancer, allogeneic T-cell therapy, hematologic malignancies, graft-versus-host disease - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here